Edwards Lifesciences Corporation (EW) Stock Rating Reaffirmed by Canaccord Genuity

Edwards Lifesciences Corporation (NYSE:EW)‘s stock had its “buy” rating reaffirmed by Canaccord Genuity in a research report issued to clients and investors on Sunday. They presently have a $155.00 price target on the medical research company’s stock. Canaccord Genuity’s price objective indicates a potential upside of 40.63% from the stock’s current price.

A number of other equities research analysts have also issued reports on the company. Barclays PLC reaffirmed an “equal weight” rating and issued a $120.00 target price on shares of Edwards Lifesciences Corporation in a research note on Saturday, September 30th. Zacks Investment Research lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $130.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. BMO Capital Markets reaffirmed a “buy” rating and issued a $132.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. Finally, William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences Corporation in a research note on Monday, August 28th. Seven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $120.75.

Shares of Edwards Lifesciences Corporation (EW) opened at 110.22 on Friday. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.45. The firm has a market cap of $23.27 billion, a PE ratio of 33.43 and a beta of 0.62. The company has a 50 day moving average price of $111.81 and a 200 day moving average price of $111.14.

Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. During the same quarter in the prior year, the company earned $0.76 EPS. Edwards Lifesciences Corporation’s revenue was up 10.9% on a year-over-year basis. On average, analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://ledgergazette.com/2017/10/10/edwards-lifesciences-corporation-ew-stock-rating-reaffirmed-by-canaccord-genuity.html.

In related news, VP Catherine M. Szyman sold 4,681 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $115.78, for a total value of $541,966.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction on Friday, July 28th. The shares were sold at an average price of $114.68, for a total value of $607,804.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 182,201 shares of company stock valued at $20,768,154. 2.13% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in EW. Sabal Trust CO boosted its position in Edwards Lifesciences Corporation by 0.5% in the 2nd quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock valued at $347,000 after buying an additional 14 shares during the last quarter. Alps Advisors Inc. boosted its position in Edwards Lifesciences Corporation by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock valued at $603,000 after buying an additional 14 shares during the last quarter. Alexandria Capital LLC boosted its position in Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares during the last quarter. M Holdings Securities Inc. boosted its position in Edwards Lifesciences Corporation by 1.5% in the 1st quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock valued at $389,000 after buying an additional 6

A number of other equities research analysts have also issued reports on the company. Barclays PLC reaffirmed an “equal weight” rating and issued a $120.00 target price on shares of Edwards Lifesciences Corporation in a research note on Saturday, September 30th. Zacks Investment Research lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $130.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. BMO Capital Markets reaffirmed a “buy” rating and issued a $132.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. Finally, William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences Corporation in a research note on Monday, August 28th. Seven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $120.75.

Shares of Edwards Lifesciences Corporation (EW) opened at 110.22 on Friday. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.45. The firm has a market cap of $23.27 billion, a PE ratio of 33.43 and a beta of 0.62. The company has a 50 day moving average price of $111.81 and a 200 day moving average price of $111.14.

Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. During the same quarter in the prior year, the company earned $0.76 EPS. Edwards Lifesciences Corporation’s revenue was up 10.9% on a year-over-year basis. On average, analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://ledgergazette.com/2017/10/10/edwards-lifesciences-corporation-ew-stock-rating-reaffirmed-by-canaccord-genuity.html.

In related news, VP Catherine M. Szyman sold 4,681 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $115.78, for a total value of $541,966.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction on Friday, July 28th. The shares were sold at an average price of $114.68, for a total value of $607,804.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 182,201 shares of company stock valued at $20,768,154. 2.13% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in EW. Sabal Trust CO boosted its position in Edwards Lifesciences Corporation by 0.5% in the 2nd quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock valued at $347,000 after buying an additional 14 shares during the last quarter. Alps Advisors Inc. boosted its position in Edwards Lifesciences Corporation by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock valued at $603,000 after buying an additional 14 shares during the last quarter. Alexandria Capital LLC boosted its position in Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares during the last quarter. M Holdings Securities Inc. boosted its position in Edwards Lifesciences Corporation by 1.5% in the 1st quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock valued at $389,000 after buying an additional 62 shares during the last quarter. Finally, Veritable L.P. boosted its position in Edwards Lifesciences Corporation by 1.2% in the 2nd quarter. Veritable L.P. now owns 6,244 shares of the medical research company’s stock valued at $738,000 after buying an additional 71 shares during the last quarter. Hedge funds and other institutional investors own 82.12% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply